Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (BMY)
NYSE:BMY
Holding BMY?
Track your performance easily
BMY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$39.35 - $56.77
Previous Close$53.22
Volume5.35M
Average Volume (3M)12.66M
Market Cap
$107.90B
Enterprise Value$153.69B
Total Cash (Recent Filing)$6.65B
Total Debt (Recent Filing)$52.39B
Price to Earnings (P/E)―
Beta0.30
Next Earnings
Oct 31, 2024EPS Estimate
$1.51Last Dividend Ex-Date
Oct 04, 2024Dividend Yield4.45%
Share Statistics
EPS (TTM)-3.26
Shares Outstanding2,027,395,178
10 Day Avg. Volume8,452,358
30 Day Avg. Volume12,664,028
Standard Deviation0.07
R-Squared0.13
Alpha-0.00036
Financial Highlights & Ratios
Price to Book (P/B)6.34
Price to Sales (P/S)2.32
Price to Cash Flow (P/CF)11.60
P/FCF Ratio13.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.30
Enterprise Value/Gross Profit4.48
Enterprise Value/Ebitda44.66
Forecast
1Y Price Target
$52.08Price Target Upside-0.08% Downside
Rating ConsensusHold
Number of Analyst Covering16
Bristol-Myers Squibb News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceLegacy products could drive a significant revenue beat of approximately $115 million against consensus expectations of around $11.3 billion.
Product Approval And SafetyThe FDA approved BMY's Cobenfy for the treatment of schizophrenia, with the drug notably not requiring a black-box warning, which is a positive distinction as most schizophrenia antipsychotic drugs include such a warning.
Strategic AcquisitionThe successful approval of Cobenfy as a first-in-class agent provides BMY with an important growth driver, affirming the strategic decision behind the company's $12.7 billion acquisition of Karuna.
Bears Say
Competitive Landscape And Efficacy ConcernsFull asundexian Ph.3 OCEANIC-AF data showed inferior efficacy of Asun with 1.3% of stroke/systemic embolism events versus 0.4% for Eliquis.
Patent Expiration And Sales ImpactBMY's LOE cliff means 70% of 2020 revenues are off patent, with no sales growth during 2023-30 given heavy patent expiration pressures.
Product Label ConcernsThe label includes language that Cobenfy is not recommended in patients with moderate to severe renal impairment.
---
Ownership Overview
0.07% Insiders
21.35% Mutual Funds
1.05% Other Institutional Investors
53.75% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BMY FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was $39.35 and its highest was $56.77 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Currently, no data Available
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Oct 31, 2024 which is in 9 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Jul 26, 2024. The company reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.45.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Overvalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of $0.6 which represents an annual dividend yield of 4.45%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is $1.51.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,027,395,100 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of $2.07 in its last earnings report, beating expectations of $1.62. Following the earnings report the stock price went up 11.436%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Among the largest hedge funds holding Bristol-Myers Squibb’s share is PRIMECAP Management Co. It holds Bristol-Myers Squibb’s shares valued at 976M.
---
Bristol-Myers Squibb Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$52.08 (-0.08% Downside)
$52.08 (-0.08% Downside)
Blogger Sentiment
Bullish
BMY Sentiment 98%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.65%
12-Months-Change
Fundamentals
Return on Equity
-26.70%
Trailing 12-Months
Asset Growth
1.24%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
---
BMY Company Deck
---
BMY Earnings Call
Q2 2024
0:00 / 0:00
---
BMY Revenue Breakdown
27.12% Eliquis
20.02% Opdivo
13.55% Revlimid
8.00% Orencia
31.31% Other
---
BMY Stock 12 Month Forecast
Average Price Target
$52.08
▼(-0.08% Downside)
Technical Analysis
Best Analysts Covering BMY
1 Year
1 Year Success Rate
13/19 ratings generated profit
1 Year Average Return
+7.58%
reiterated a sell rating 11 days ago
Copying Terence Flynn's trades and holding each position for 1 Year would result in 68.42% of your transactions generating a profit, with an average return of +7.58% per trade.
---